https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42666 Wed 31 Aug 2022 14:05:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39575 Wed 27 Jul 2022 14:43:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13674 Wed 24 Jun 2020 12:51:30 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53345 Wed 22 Nov 2023 10:19:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22648 Wed 22 May 2019 14:50:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34644 Wed 22 May 2019 14:48:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48596 Wed 22 Mar 2023 08:46:40 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54397 Wed 21 Feb 2024 15:48:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13672 Wed 11 Apr 2018 16:23:10 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13671 Wed 11 Apr 2018 16:06:02 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13673 Wed 11 Apr 2018 15:24:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24220 A and −174 G>C) correlate with MS susceptibility, but with varying results. In the present study, we analyzed these polymorphisms, together with an additional polymorphism (−572 G>C) in 279 healthy controls and 509 patients with MS. We found no significant differences between MS patients and healthy controls for the different −597 or −174 IL6 promoter alleles or genotypes. There was a slight reduction in the percentage of individuals with MS who carried a C allele at position −572, although this was not significant after correction for multiple comparisons. Interestingly, however, the −572 C allele showed a significant correlation with the MS severity score, suggesting a possible role in disease progression.]]> Wed 11 Apr 2018 15:18:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28397 Wed 11 Apr 2018 15:14:13 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25641 Wed 11 Apr 2018 15:12:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26643 Wed 11 Apr 2018 13:39:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13696 Wed 11 Apr 2018 12:04:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28923 Wed 11 Apr 2018 10:33:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13692 Wed 11 Apr 2018 09:50:56 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39516 Wed 10 Aug 2022 11:31:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53300 Tue 21 Nov 2023 12:02:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54378 Tue 20 Feb 2024 20:24:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52582 Tue 17 Oct 2023 15:55:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51306 Thu 31 Aug 2023 14:27:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51627 Thu 23 Nov 2023 14:26:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36736 Thu 02 Jul 2020 16:31:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41240 Sat 30 Jul 2022 12:19:30 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12845 T at 3p24.1 (odds ratio [OR], 1.17; p = 1.6 × 10⁻⁸) near EOMES, rs2150702^G in the second intron of MLANA on chromosome 9p24.1 (OR, 1.16; p = 3.3 × 10⁻⁸), and rs6718520^A in an intergenic region on chromosome 2p21, with THADA as the nearest flanking gene (OR, 1.17; p = 3.4 × 10⁻⁸). The 3 new loci do not have a strong cis effect on RNA expression in PBMCs. Ten other susceptibility loci had a suggestive p < 1 × 10⁻⁶, some of these loci have evidence of association in other inflammatory diseases (ie, IL12B, TAGAP, PLEK, and ZMIZ1). Interpretation: We have performed a meta-analysis of GWAS in MS that more than doubles the size of previous gene discovery efforts and highlights 3 novel MS susceptibility loci. These and additional loci with suggestive evidence of association are excellent candidates for further investigations to refine and validate their role in the genetic architecture of MS.]]> Sat 24 Mar 2018 08:17:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20798 Sat 24 Mar 2018 08:05:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17471 Sat 24 Mar 2018 08:04:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18887 Sat 24 Mar 2018 08:03:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18888 Sat 24 Mar 2018 08:03:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18886 Sat 24 Mar 2018 08:03:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19533 95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b (p≤0.001). No differences in 12-month confirmed progression of disability were observed. Conclusion: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.]]> Sat 24 Mar 2018 08:02:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19821 Sat 24 Mar 2018 07:56:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20329 Sat 24 Mar 2018 07:55:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19680 Sat 24 Mar 2018 07:53:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30101 Sat 24 Mar 2018 07:37:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29942 -23). A reciprocal relationship was seen for ambient ultraviolet radiation (UVR), with a significantly increasing AAO for patients with MS per each quartile increment of ambient UVR (p=1.56×10^-17). We found that the AAO of female patients was ~5 months earlier than male patients (p=0.002). AAO of progressive-onset patients with MS were ~9 years later than relapsing-onset patients (p=1.40×10^-265). Conclusions: An earlier AAO in higher latitude regions was found in this worldwide European-descent cohort and correlated inversely with variation in latitudinal UVR. These results suggest that environmental factors which act at the population level may significantly influence disease severity characteristics in genetically susceptible populations.]]> Sat 24 Mar 2018 07:31:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25354 Sat 24 Mar 2018 07:24:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23863 Sat 24 Mar 2018 07:12:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24704 85% loss of 'pore' function of the P2X7 receptor measured by ATP-induced ethidium uptake. Analysis shows Arg307Gln always occurred with 270His suggesting a single 307Gln-270His haplotype which confers dominant negative effects on P2X7 function and protection against MS. Modelling based on the homologous zP2X4 receptor showed Arg307 is located in a region rich in basic residues located only 12Å from the ligand binding site. Our data show the protective effect against MS of a rare genetic variant of P2RX7 with heterozygotes showing near absent proinflammatory 'pore' function.]]> Sat 24 Mar 2018 07:10:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49703 Mon 29 May 2023 13:00:52 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37732 p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p <0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p <0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p <0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). Interpretation: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.]]> Mon 29 Mar 2021 13:09:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38628 + T cells of relapsing–remitting (RR) MS patients compared to healthy controls and identified differentially methylated regions (DMRs) in HLA-DRB1 and RNF39. This study aimed to investigate the DNA methylation profiles of the CD4⁺ T cells of progressive MS patients. DNA methylation was measured in two separate case/control cohorts using the Illumina 450K/EPIC arrays and data was analysed with the Chip Analysis Methylation Pipeline (ChAMP). Single nucleotide polymorphisms (SNPs) were assessed using the Illumina Human OmniExpress24 arrays and analysed using PLINK. Expression was assessed using the Illumina HT12 array and analysed in R using a combination of Limma and Illuminaio. We identified three DMRs at HTR2A, SLC17A9 and HDAC4 that were consistent across both cohorts. The DMR at HTR2A is located within the bounds of a haplotype block; however, the DMR remained significant after accounting for SNPs in the region. No expression changes were detected in any DMRs. HTR2A is differentially methylated in progressive MS independent of genotype. This differential methylation is not evident in RRMS, making it a potential biomarker of progressive disease.]]> Mon 29 Jan 2024 17:52:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51965 Mon 25 Sep 2023 08:53:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36719 Mon 24 Aug 2020 10:45:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53246 Mon 20 Nov 2023 10:14:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46218 Mon 14 Nov 2022 12:12:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50986 Mon 14 Aug 2023 15:59:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54767 Mon 11 Mar 2024 15:00:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25306 Mon 06 Mar 2023 17:55:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41309 Mon 01 Aug 2022 12:30:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41083 Fri 22 Jul 2022 17:11:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42294 Fri 19 Aug 2022 14:58:38 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51076 Fri 18 Aug 2023 09:03:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54701 Fri 08 Mar 2024 12:07:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52991 Fri 03 Nov 2023 16:05:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49799 Fri 02 Jun 2023 17:06:47 AEST ]]>